White Papers

  1. The TIDES Manufacturing Mandate: Why Incrementalism Fails And Integration Prevail 5/7/2026

    Manufacturing strategies for peptides and oligonucleotides are being reshaped by scale, complexity, and chronic use. An integrated, end‑to‑end approach shows how early design decisions can prevent costly bottlenecks later.

  2. The Analytical Advantage Across The Development Lifecycle 5/7/2026

    Integrated, regulatory‑ready analytics help accelerate development, strengthen submissions, and ensure consistent product quality throughout the pharmaceutical lifecycle.

  3. Precision By Design: Drug Innovation Through Structure-Based Drug Design (SBDD) 5/6/2026

    Leverage structure-based drug design to gain deeper molecular insights, prioritize high-potential candidates, and accelerate your path from discovery to clinic.

  4. Accelerating Small Molecule Protein Degrader Development Using High-Content Imaging 5/6/2026

    High‑content imaging enables rapid discovery and optimization of small‑molecule protein degraders by delivering multiparametric, single‑cell insights that accelerate hit identification, SAR development, and lead advancement.

  5. (Cross-) Contamination Control Through Effective Equipment Cleaning 5/6/2026

    Discover science-driven cleaning strategies that reduce cross-contamination, enable safe multiproduct manufacturing, and support faster, flexible GMP changeovers.

  6. The Importance Of Polymorph Screenings 5/6/2026

    Discover how systematic polymorph screening reduces development risk, safeguards product performance, and enables confident solid‑form selection across the drug development lifecycle.

  7. Deciphering Nanoparticle Properties With AF4 5/6/2026

    Discover how risk‑based, phase‑appropriate synthesis enables safe, efficient production of highly potent compounds while balancing speed, worker safety, and regulatory readiness in early development.

  8. Streamlining Early Drug Development: Efficient Synthesis Of Highly Potent Compounds 5/6/2026

    Discover how risk‑based, phase‑appropriate synthesis enables safe, efficient production of highly potent compounds while balancing speed, worker safety, and regulatory readiness in early development.

  9. Drug Substance For Early Clinical Phase Initiation 5/6/2026

    Explore how proactive nitrosamine impurity risk assessment protects early clinical drug supply, minimizes development delays, and enables confident progression to first‑in‑human studies.

  10. Accelerating Drug Development: Solid State Chemistry And Strategic Outsourcing 5/6/2026

    Discover how phase‑appropriate solid‑state chemistry and strategic outsourcing reduce risk, speed development timelines, and enable confident solid‑form selection for complex small‑molecule programs.